Chemotherapy News and Research

Latest Chemotherapy News and Research

Alimta approved as first treatment for Mesothelioma, a deadly cancer caused by asbestos

Lilly UK announced today that Alimta( (pemetrexed) will be available shortly for the treatment of people diagnosed with mesothelioma, a cancer of the lining of the lungs for which there is no known cure. Pemetrexed is the first licenced treatment for malignant pleural mesothelioma, in combination with cisplatin.

1 Nov 2004

Micro-array technology is revolutionising current drug development

Gene expression micro-array technology is benefiting all phases of the discovery, development and subsequent use of new cancer therapeutics

29 Oct 2004

Higher radiation doses helps patients with advanced non-small cell lung cancer live longer

Treating patients with advanced non-small cell lung cancer more aggressively by giving them higher doses of radiation helps keep the disease from spreading and allows some patients to live longer

28 Oct 2004

Understanding the impact of breast cancer beyond treatment

Monash University and the Jean Hailes Foundation are assessing the key physical and emotional issues faced by women following breast cancer diagnosis and treatment as part of a five-year study.

26 Oct 2004

Project to refine and fine-tune radiotherapy treatment for cancer

The EU-funded GENEPI project will provide the facility for essential research which will improve and refine radiotherapy for European cancer patients

26 Oct 2004

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

New help to explain treatments for colorectal cancer

To help patients and their families better understand how different treatments work to cure colorectal cancer, the American Society for Therapeutic Radiology and Oncology has published the new patient information brochure Radiation Therapy for Colorectal Cancer: Facts to Help People Understand Their Treatment Options.

25 Oct 2004

Boehringer Ingelheim - New Drug Application (NDA) for tipranavir

The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review of the NDA. Priority review designation is based upon whether a drug provides a significant improvement in the treatment of a serious or life-threatening disease.

25 Oct 2004

Blocking gene opens avenues for treating prostate cancer

Cancer Research UK scientists in Oxford have found a new way to make prostate cancer succumb more readily to currently used treatments.

22 Oct 2004

Tamoxifen use for the treatment of breast cancer is not associated with an increased risk of stroke

Tamoxifen use for the treatment of breast cancer is not associated with an increased risk of stroke, according to a new study in the October 20 issue of the Journal of the National Cancer Institute. However, chemotherapy use is associated with an increased risk of stroke, regardless of tamoxifen use.

21 Oct 2004

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Researchers at Virginia Commonwealth University’s Massey Cancer Center received a prestigious award and a $600,000 grant from the V Foundation for Cancer Research, one of the nation’s leading organizations devoted exclusively to funding cancer research.

20 Oct 2004

Discovery might improve design, effectiveness of anti-cancer drugs

Working with an enzyme that degrades anti-cancer drugs in humans, University of North Carolina at Chapel Hill biochemists and colleagues have made a discovery that they believe eventually could help improve such drugs’ design and effectiveness.

18 Oct 2004

Presentation of the most recent and advanced work in the rapidly progressing field of fertility preservation

Each year approximately 50,000 women under the age of 40 are diagnosed with breast cancer. Treatments vary but most involve the administration of chemotherapeutic agents or radiation which can disrupt ovarian function or damage a patient’s eggs.

18 Oct 2004

Significant steps to fight a deadly childhood muscle cancer

University of Utah scientists have taken significant steps to fight a deadly childhood muscle cancer by identifying some of the genetic events that cause the disease and then engineering mice that develop the tumors.

16 Oct 2004

Study examines fertility concerns among young women with breast cancer

A new study shows that concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one-third of young patients.

12 Oct 2004

New research suggests that cancer cells can be reformed

New research by Dean Felsher, MD, PhD, assistant professor of medicine (oncology) and of pathology at the Stanford University School of Medicine, suggests that cancer cells can be reformed.

12 Oct 2004

Researchers identify common mutation in T-cell acute lymphocytic leukemia

Researchers at Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) have made a breakthrough discovery, identifying a common mutation in T-cell acute lymphocytic leukemia (T-ALL), an important form of cancer in children and adolescents.

11 Oct 2004

Support groups help women with breast cancer gene mutations

A new study finds support groups can relieve the anxiety and depression associated with carrying BRCA1 or 2 gene mutations, the so-called "cancer genes."

11 Oct 2004

Prostate cancer patients who no longer respond to hormone therapy may benefit from a combination of docetaxel and estramustine

Prostate cancer patients whose cancer has spread to other parts of the body and who no longer respond to hormone therapy may benefit from a combination of the cancer drugs docetaxel and estramustine, according to a new study published in the Oct. 8 issue of the New England Journal of Medicine.

8 Oct 2004

Men with advanced, incurable prostate cancer can benefit from docetaxel

An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

7 Oct 2004